Head and Neck Cancer Clinical Trial
Official title:
An Exploratory, Open Label, Single Center Study of [F-18]HX4
[F-18]HX4 is being developed as a diagnostic radiopharmaceutical for PET imaging. This trial
is looking at the safety of [F-18]HX4.
The Sponsor is seeking to determine if [F-18]HX4 may serve as a clinically useful hypoxia
marker in diagnostic imaging, allowing the rational application of hypoxia related therapies
to those patients most likely to benefit from them.
Tumor hypoxia, a situation where tumor cells have been deprived of oxygen, caused cancer
cells to become more resistant to the effects of radiotherapy and chemotherapy.
A non-invasive study characterizing tumor hypoxia would facilitate the development of
targeted therapies.
The population to be studied consists of a total of ten (10) adult subjects, including, four
normal volunteers and six cancer subjects, the latter with a confirmed diagnosis of head and
neck cancer, as defined by the protocol eligibility criteria.
The objectives of this exploratory study are to:
- Gain information on bio-distribution of [F-18]HX4, and to evaluate the PET images of
[F-18]HX4 for resolution, signal to background ratio for both intermediate levels of
oxygenation, and at extreme levels hypoxia
- Use this eIND in order to obtain the necessary information to file an IND application
with the FDA. The information collected under this exploratory study will not be used
for diagnostic purposes, to assess the subject's response to therapy, or for clinical
management of the subject.
- Begin collection of baseline imaging data
- Collect [F-18]HX4 metabolism data
- Gain information to improve study design and the conduct of future trials
This investigation will be conducted as an exploratory, open-label, non-randomized,
uncontrolled, single center, safety study.
The trial is expected to begin subject enrollment in early January 2008 and end subject
participation in June 2008.
The duration of an individual subject's participation includes a screening visit, followed
by participation in the actual study starting with the day of dosing with imaging sessions
lasting several hours, concluding with a next day safety follow-up visit.
Individual doses of [F-18]HX4 shall not exceed 20 mCi. The IP will be administered through a
previously placed suitably sized angiocatheter or a butterfly needle. Prior to injection,
qualified site personnel will assay the dose. After IP administration several PET imaging
series will be acquired. Also, in order to assess major organ function and electrolyte
levels, a metabolites analysis will be performed for this study from predose to 90 minutes
postdose.
In order to determine the quantity of [F-18]HX4 and labeled metabolites excreted by the
kidney,urine will be collected and pooled at the designated intervals after administration
of the investigational product. This excretion data will provide supportive information for
calculating human dosimetry estimates from PET imaging biodistribution data collected in
human subjects.
For cancer subjects, a tissue biopsy will have been taken or be scheduled to be performed.
The biopsy sample will be examined for hypoxic biomarker(s) using immunohistochemistry
methods.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |